Immunity
Peptides
Compound profile

LL-37: Cathelicidin Antimicrobial Peptide

LL-37 is the C-terminal cleavage product of hCAP18, the sole human cathelicidin.

On this page

What it is

LL-37 is a 37-amino-acid amphipathic peptide released from its precursor hCAP18 by proteolytic cleavage. The only human cathelicidin identified.

Evidence snapshot

Category: Immunity. Status: Preclinical. See the references section below for the underlying primary sources.

Mechanism

Exerts antimicrobial activity through membrane disruption and immunomodulatory effects through interactions with TLRs, formyl peptide receptors, and other receptors.

Key research findings

Studied across antimicrobial, immunomodulatory, and wound-healing contexts. Particular interest in chronic inflammatory conditions including psoriasis and rosacea.

Limits of the evidence

Predominantly preclinical. Dose, route, and target population questions remain. Antimicrobial peptides as drugs have had mixed clinical development success.

Continue reading

Tissue Repair

BPC-157

Synthetic pentadecapeptide derived from a gastric juice protein, studied across hundreds of preclinical reports for tissue regeneration and cytoprotection.
Read Guid
Tissue Repair

TB-500 (Thymosin Beta-4 fragment)

Synthetic fragment of Thymosin Beta-4, a 43-amino-acid peptide investigated for its role in actin regulation, cell migration, and wound healing.
Read Guid
Peptide Protocols

BPC-157 + TB-500

Combined tissue-repair peptides with complementary mechanisms — the synergy hypothesis examined critically against the available preclinical record.
Read Guid
Growth Hormone · Research

Ipamorelin

Selective pentapeptide agonist of the growth hormone secretagogue receptor (GHSR-1a) studied for targeted GH release with minimal effect on cortisol, ACTH and prolactin.
Read Guid